Results 211 to 220 of about 115,857 (253)

Immunomodulatory role of megakaryocytes in the hematopoietic niche of myeloproliferative neoplasms. [PDF]

Haematologica
Yang X, Lee S, Masarik K, Ahmed T, Zheng L, Zhan H.   +5 more
europepmc   +1 more source

Inhibitory HLA-C/KIR2DL2 Interactions and KIR Allelic Polymorphisms Are Associated With Susceptibility to Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. [PDF]

EJHaem
Shivarov V, Tsvetkova G, Hadjiev E, Ivanova M.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Thrombosis in Myeloproliferative Neoplasms

Seminars in Thrombosis and Hemostasis, 2014
Thrombotic events are very frequent and represent the main cause of morbidity and mortality in patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), mainly polycythemia vera and essential thrombocythemia. Pathogenesis of blood clotting activation in these diseases is multifactorial, and it involves various abnormalities of
Marina Marchetti, Anna Falanga
exaly   +4 more sources

Pediatric Myeloproliferative Neoplasms

Clinics in Laboratory Medicine, 2021
Myeloproliferative neoplasms can present early in life and may present a diagnostic challenge. Very few studies have focused on the diagnosis, prognosis, and therapy for pediatric myeloproliferative neoplasms. This article focuses on chronic myeloid leukemia, essential thrombocythemia, polycythemia vera, and primary myelofibrosis in children.
Farah, El-Sharkawy, Elizabeth, Margolskee   +1 more
openaire   +2 more sources

Myeloproliferative Neoplasms with Monocytosis

Current Hematologic Malignancy Reports, 2021
Myeloproliferative neoplasms (MPN) are a heterogeneous group of hematopoietic stem cell neoplasms comprising of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) that share driver mutations (JAK2/CALR/MPL) resulting in constitutive activation of JAK/STAT and other signaling pathways.
Erika Morsia, Naseema Gangat
openaire   +2 more sources

Diagnostic Approach to Myeloproliferative Neoplasms and Myelodysplastic/Myeloproliferative Neoplasms

Advances in Anatomic Pathology
The International Consensus Classification (ICC) updated in 2022 the World Health Organization (WHO) classification of hematopoietic tumors (2016 revision of the 4th edition WHO classification). Although the major categories of myeloid neoplasms remained unchanged from the prior WHO classification, many disease entities including those in the ...
Sonam Prakash, Attilio Orazi
openaire   +2 more sources

Inflammation and myeloproliferative neoplasms

Journal of Autoimmunity, 2017
Myeloproliferative neoplasms (MPN) include three main entities: Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Myelofibrosis (MF). MPN represent a unique model of the relationship between the clonal development of a hematologic malignancy and chronic inflammation.
F. Lussana, A. Rambaldi
openaire   +2 more sources

Myeloproliferative Neoplasms, Myelodysplastic/Myeloproliferative Neoplasms, and Myelodysplastic Syndromes

2021
In the 2017 WHO classification, chronic myeloid neoplasms include myeloproliferative neoplasms (MPNs), myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), myelodysplastic syndrome (MDS), mastocytosis and myeloid/lymphoid neoplasms with eosinophilia with rearrangements in FGFR1, PDGFRA, PDGFRB, or PCM1-JAK2 fusions.
Julie Li, Gang Zheng
openaire   +1 more source